CORC

在结果中检索

CORC

浏览/检索结果: 共40条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects 期刊论文
DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 卷号: 15, 页码: 2947-2959
作者:  Qian, Hongjie;  Chen, Qian;  Lang, Liyu;  Zou, Yang;  Pu, Huahua
收藏  |  浏览/下载：38/0  |  提交时间：2021/08/17
Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 卷号: 63, 期号: 24, 页码: 15153-15186
作者:  Zheng, Wei;  Wang, Zhen;  Jiang, Xiangrui;  Zhao, Qingjie;  Shen, Jingshan
收藏  |  浏览/下载：26/0  |  提交时间：2021/05/24
Metabolomics reveals metabolite changes of patients with pulmonary arterial hypertension in China 期刊论文
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 页码: 13
作者:  Chen, Chenyang;  Luo, Fei;  Wu, Panyun;  Huang, Yiyuan;  Das, Avash
收藏  |  浏览/下载：34/0  |  提交时间：2020/03/18
Pharmacokinetics-Driven Optimization of 4(3H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 卷号: 62, 期号: 10, 页码: 4979-4990
作者:  Wang, Zhen;  Jiang, Xiangrui;  Zhang, Xianglei;  Tian, Guanghui;  Yang, Rulei
收藏  |  浏览/下载：40/0  |  提交时间：2020/07/01
Pharmacokinetics-Driven Optimization of 4(3H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 卷号: 62, 期号: 10, 页码: 4979-4990
作者:  Wang, Z (Wang, Zhen)[ 1 ];  Jiang, XR (Jiang, Xiangrui)[ 1 ];  Zhang, XL (Zhang, Xianglei)[ 1,2 ];  Tian, GH (Tian, Guanghui)[ 3 ];  Yang, RL (Yang, Rulei)[ 3 ]
收藏  |  浏览/下载：140/0  |  提交时间：2019/06/28
Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study 期刊论文
EUROPEAN RESPIRATORY JOURNAL, 2019, 卷号: 53, 期号: 2
作者:  Qian, Junyan;  Li, Mengtao;  Zhang, Xiao;  Wang, Qian;  Zhao, Jiuliang
收藏  |  浏览/下载：18/0  |  提交时间：2019/12/11
Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study 期刊论文
The European respiratory journal, 2019, 卷号: 53, 期号: 2
作者:  Qian J.;  Li M.;  Zhang X.;  Wang Q.;  Zhao J.
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/11
Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors 期刊论文
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 卷号: 22, 期号: 5, 页码: 921-928
作者:  Zhang, Na;  Li, Mengtao;  Qian, Junyan;  Wang, Qian;  Zhao, Jiuliang
收藏  |  浏览/下载：10/0  |  提交时间：2019/12/11
Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study 期刊论文
2019, 卷号: 53, 期号: 2
作者:  Qian, Junyan;  Li, Mengtao;  Zhang, Xiao;  Wang, Qian;  Zhao, Jiuliang
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03
Mir-455-3p-1 represses FGF7 expression to inhibit pulmonary arterial hypertension through inhibiting the RAS/ERK signaling pathway 期刊论文
2019, 卷号: 130, 页码: 23-35
作者:  Zhou, Chenghui;  Chen, Yu;  Kang, Wenying;  Lv, Hong;  Fang, Zhongrong
收藏  |  浏览/下载：12/0  |  提交时间：2020/01/03
miR-455-3p-1  FGF7  RAS  ERK  PAH  

©版权所有 ©2017 CSpace - Powered by CSpace